Branded pharma’s Q1 earnings delivered a mixed but mostly positive report—revenues beat estimates by 3.5% and stocks rose an average of 8.5%. Corcept, despite missing earnings and revenue forecasts by over 11%, boosted its full-year guidance and saw its stock soar 100% to $96.50. Meanwhile, Eli Lilly dominated the quarter with a 55% revenue surge to $19.8B, crushing estimates by 14% and raising its full-year outlook—its stock jumped 40% to $1,197, the biggest gain in the group.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
